NR3C1 and Hyperglycemia: Furthermore, anti-sense oligonucleotides directed against the GR have shown liver-specific effects, decreasing fasting hyperglycemia, reducing fasting insulin levels and decreasing GC-stimulated hepatic glucose output [129,130,131,132].